Ojas Mehta

Background and Experience

Ojas brings more than 20 years of experience in academic technology transfer and biotech business development. He spent 11 years leading the technology transfer team at Massachusetts Eye and Ear, where he was responsible for licensing, strategic alliances, commercialization of the institution’s AAV program, and management of the MEE Summit Fund.

He later transitioned to industry as a member of the Business Development team at CureVac, focusing on mRNA therapeutics in immuno-oncology and rare diseases. Most recently, Ojas led the out-licensing of Inari’s proprietary CRISPR system for human therapeutic applications.